Replies to post #250503 on Biotech Values

[DewDiligence]

FDMT—(-34%)—reports purportedly-positive interim phase-2 data_in wAMD:

https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html

FDMT has risen either sharply or dropped sharply on each interim release from this trial.